166 related articles for article (PubMed ID: 28440416)
1. FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Tsuchida N; Ikeda MA; Ιshino Υ; Grieco M; Vecchio G
Int J Oncol; 2017 Jun; 50(6):2043-2048. PubMed ID: 28440416
[TBL] [Abstract][Full Text] [Related]
2. Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.
Vecchio G; Parascandolo A; Allocca C; Ugolini C; Basolo F; Moracci M; Strazzulli A; Cobucci-Ponzano B; Laukkanen MO; Castellone MD; Tsuchida N
Oncotarget; 2017 Apr; 8(16):27075-27092. PubMed ID: 28404918
[TBL] [Abstract][Full Text] [Related]
3. Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells.
Ezawa I; Sawai Y; Kawase T; Okabe A; Tsutsumi S; Ichikawa H; Kobayashi Y; Tashiro F; Namiki H; Kondo T; Semba K; Aburatani H; Taya Y; Nakagama H; Ohki R
Cancer Sci; 2016 Jun; 107(6):734-45. PubMed ID: 26998741
[TBL] [Abstract][Full Text] [Related]
4. Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.
Wang Y; Hardin H; Chu YH; Esbona K; Zhang R; Lloyd RV
Endocr Pathol; 2019 Dec; 30(4):262-269. PubMed ID: 31468286
[TBL] [Abstract][Full Text] [Related]
5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of α-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface.
Cheng TC; Tu SH; Chen LC; Chen MY; Chen WY; Lin YK; Ho CT; Lin SY; Wu CH; Ho YS
Oncotarget; 2015 Aug; 6(25):21283-300. PubMed ID: 26204487
[TBL] [Abstract][Full Text] [Related]
7. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
[No Abstract] [Full Text] [Related]
8. PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.
Chiappetta G; Valentino T; Vitiello M; Pasquinelli R; Monaco M; Palma G; Sepe R; Luciano A; Pallante P; Palmieri D; Aiello C; Rea D; Losito SN; Arra C; Fusco A; Fedele M
Oncotarget; 2015 Mar; 6(7):5310-23. PubMed ID: 25595894
[TBL] [Abstract][Full Text] [Related]
9. [Corrigendum] FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.
Int J Oncol; 2017 Sep; 51(3):996-0. PubMed ID: 28731163
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of α-l-fucosidase 1 suppresses glioma progression by enhancing autophagy and inhibiting macrophage infiltration.
Xu L; Li Z; Song S; Chen Q; Mo L; Wang C; Fan W; Yan Y; Tong X; Yan H
Cancer Sci; 2020 Jul; 111(7):2284-2296. PubMed ID: 32314457
[TBL] [Abstract][Full Text] [Related]
12. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
[TBL] [Abstract][Full Text] [Related]
14. Alpha-L-fucosidase-1 is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma.
Ishida S; Kayamori K; Sakamoto K; Yukimori A; Kugimoto T; Harada H; Ikeda T
Pathol Int; 2019 Feb; 69(2):76-85. PubMed ID: 30729618
[TBL] [Abstract][Full Text] [Related]
15. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
16. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
[TBL] [Abstract][Full Text] [Related]
17. Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations.
Oishi N; Vuong HG; Mochizuki K; Kondo T
Endocr Pathol; 2020 Dec; 31(4):359-366. PubMed ID: 33058026
[TBL] [Abstract][Full Text] [Related]
18. Altered mRNA Expression of Fucosyltransferases and Fucosidase Predicts Prognosis in Human Oral Carcinoma.
Mehta K; Patel K; Pandya S; Patel P
Int J Mol Cell Med; 2021; 10(2):123-131. PubMed ID: 34703796
[TBL] [Abstract][Full Text] [Related]
19. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
20. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
